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AbstrACt
Objective Compare vitamin D levels in opioid dependence 
and control population and adjust for relevant confounding 
effects. Nuclear hormone receptors (including the vitamin 
D receptor) have been shown to be key transducers and 
regulators of intracellular metabolism and comprise an 
important site of pathophysiological immune and metabolic 
dysregulation potentially contributing towards pro-ageing 
changes observed in opioid-dependent patients (ODPs).
Design Longitudinal prospective comparing ODPs with 
general medical controls (GMCs).
setting Primary care.
Participants Prospective review comparing 1168 ODP 
(72.5% men) and 415 GMC (51.6% men, p<0.0001). Mean 
ages were 33.92±0.31 (mean±SEM) and 41.22±1.32 years, 
respectively (p<0.0001). Opioid use in the ODP has been 
previously reported and shown to be typical.
Interventions Nil. Observational study only.
Primary and secondary outcomes Serum vitamin D 
levels and relevant biochemical parameters.
results Vitamin D levels were higher in the ODP 
(70.35±1.16 and 57.06±1.81 nmol/L, p<0.0001). The 
difference in ages between the two groups was handled in an 
age-matched case–control subanalysis and also by multiple 
regression. Sexes were analysed separately. The age:status 
(or age:time:status) was significant in case–control, cross-
sectional and longitudinal analyses in both sexes (p<0.05). 
Modelled vitamin D was 62.71 vs 57.81 nmol/L in the two 
groups. Time-dependent mixed-effects models quadratic in 
age outperformed linear-only models (p=0.0377). ODP vitamin 
D was shown to vary with age and to correlate with alanine 
aminotransferase establishing it as a biomarker of age in this 
group. Hepatitis C seronegativity was significant in regression 
models (from p=0.0015).
Conclusion Vitamin D was higher in ODP in both sexes 
in bivariate, cross-sectional, case–control and longitudinal 
analyses and was robust to the inclusion of metabolic and 
immune biomarkers. That Hepatitis C seronegativity was 
significant suggests opioid dependence has an effect beyond 
simply that of its associated hepatitides. This finding may 
relate to the accelerated ageing process previously described 
in opioid dependence.
IntrODuCtIOn 
Vitamin D and its nuclear steroid receptor have 
been implicated in a wide range of physiological 
and developmental functions including skel-
etal, immunological, muscle strength and 
tendon function, metabolic syndrome and 
obesity, cardiovascular disease, endocrine 
disorders including diabetes, neuropsychiatric 
disorders, oncogenesis of several cancers, devel-
opment and many cellular function.1–4 Many of 
these age-related morbidities are increasingly 
associated with opiate use.5–9 However, a litera-
ture search of the PubMed, Scopus and Ebsco 
Host online databases revealed no reports of 
the impact of opiate dependency on vitamin 
levels, other than a single report of its associ-
ation with the adequacy of pain control in a 
cohort of patients with chronic pain.10 
This whole area has recently been shown 
to be of enormous clinical importance by 
the increasing significance of vitamin D in 
multiple sclerosis11–17although this relation-
ship remains controversial.18–20
The subject is of importance for several 
reasons. There are several reports of elevated 
rates of osteoporosis/osteopaenia in opioid-de-
pendent cohorts.5 8 21 Higher levels of calcium, 
phosphate and their solubility product have 
strengths and limitations of this study
 ► Strengths of this study included its large sample 
size, prospective and longitudinal design and real-
world sampling in primary care.
 ► The involvement of nuclear hormone receptor 
signalling in coordinating metabolic and immune 
systems provides an important insight into a major 
network of pathways which may contribute to the 
altered pathophysiological experience of drug 
dependent cohorts.
 ► Study weaknesses included the unavailability of 
socioeconomic or occupational data which may 
impact on the amount of sun exposure derived from 
differing lifestyles and vocational exposure.
 ► Vitamin D receptor assays and assays for the various 
vitamin D metabolites were also not available to this 
study.
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previously been reported in opioid-dependent patients 
(ODPs).22
Increased vascular stiffness has also been reported in 
both male and female patients.7 23 It may be that higher 
levels of vascular stiffness—and vascular age—are causally 
associated with disruptions of vitamin D physiology. More-
over, a number of tumours have also been noted to be 
seen at higher incidence in ODPs24–26 which may relate to 
either altered nutritional, metabolic or immune factors. 
Chronic muscle and joint pain is also a common feature 
of opioid withdrawal which many dependent patients 
experience on a daily basis and is known not to respond 
to non-narcotic analgesics.10 27
The evidence from numerous sources is remarkably 
consistent and increasingly strong for a pattern of accel-
erated ageing in opioid dependence.7 23 Subcellular 
oxidative damage particularly arising from immune 
mechanisms is increasingly emerging as a principal deter-
minant of ageing processes.28 29 As an important modifier 
of immune dysregulation,30–34 it is therefore plausible that 
vitamin D physiology may impinge on the ageing process 
in a clinically significant manner and may be of particular 
relevance to the immune dysregulation well described in 
opioid dependence35–39 and the accompanying syndrome 
of accelerated ageing.
Moreover, complex interactions are increasingly being 
documented between nutritional, immune, gastrointestinal 
and metabolic biomarkers40–42 making multiway interactions 
both analytically feasible and physiologically meaningful.43
The following study was therefore conducted prospec-
tively to ascertain (i) the comparative levels of vitamin D in 
opiate-dependent and non-dependent clinical populations 
including sex differentials and comparative levels of hypovi-
taminosis D; (ii) to document the relationship of chronolog-
ical age with changes in vitamin D status in dependent and 
non-dependent groups and therefore its role as a potential 
biomarker of ageing and (iii) to document significant associ-
ated changes in metabolic and innate and adaptive immune 
function with vitamin D levels. As our clinic sees significant 
numbers of both ODPs and non-dependent patients, we are 
ideally suited to compare opioid-dependent and non-de-
pendent cohorts.
MethODs
Patient selection
All ODPs and general medical controls (GMCs) attended 
a single metropolitan outpatient clinic, with data collected 
by retrospective review of patient records. All patients in 
whom a vitamin D assay was requested were included in 
the analysis. There was no selection of patients based on 
age. Hepatitis C serology was routinely only performed on 
opiate-dependent patients, and was used as a surrogate 
marker for retrospectively identifying opiate-dependent 
patients. Hence, patients were considered to be opioid 
dependent where the hepatitis C test was performed or 
the hepatitis C virus (HCV) RNA PCR test was positive. In a 
few cases, data were manually curated to correct anomalies. 
The two study groups are thus described as being ODPs and 
GMCs. Other blood tests were taken as clinically required in 
the process of routine medical care.
Pathology analysis
As a high rate of abnormally low vitamin D levels was 
quickly noted in all our patients, this test was ordered 
routinely on all patients who required clinical pathology to 
be performed. All clinical pathology was undertaken by the 
Queensland Medical Laboratory (QML) which is accred-
ited by the National Association of Testing Authorities 
Australia to the Australian Laboratory standard AS-15189. 
QML is also accredited to the international standard ISO 
9001 the international laboratory clinical standard. The 
form of vitamin D measured was 25-hydroxycholecalciferol. 
The calcium–phosphate solubility product was defined as is 
usual in chemistry as the product of the cube of the serum 
calcium concentration and the square of the phosphate 
concentration as previously described.22
statistics
The pathology results were downloaded as an Excel 
spreadsheet from QML for the period 1995–2017. Data 
are listed as mean±SEM. Categorical data were compared 
in EpiInfo V.7.2.0.1 from Centres for Disease control 
in Atlanta, Georgia, USA using the adjusted Mantel-
Haenszel statistic. Bivariate statistics were compared by 
categories in Statistica V.7.1 from Statsoft, Oklahoma, 
USA. Student’s test for t with separate variances was 
utilised as indicated by the Levene test. This is reported 
in table 1 as fractional df.
‘R’ V.3.3.2 was downloaded from the University of 
Melbourne Central ‘R’ Archive Network mirror. Multiple 
regression was performed in ‘R’ and graphs were drawn in 
R using the ggplot2 package. Loess (localised polynomial 
curves) were drawn at a span=0.95. Multiple regression 
model reduction was performed by the classical method 
with deletion of the least significant term until only signif-
icant terms remained. Deidentified confidential data may 
be made available to interested readers and researchers on 
written request to the authors. Continuous data of such as 
vitamin D, alanine aminotransferase (ALT), serum globu-
lins and C-reactive protein were log transformed in multiple 
regression analyses as indicated by the results of the Shapiro 
test. Chronological age was not log transformed in the inter-
ests of improving model fit. Linear and polynomial models 
were compared using analysis of variance (ANOVA) tests in 
R. Missing data were case-wise deleted. All t-tests were two 
tailed. p Value <0.05 was considered significant.
ethics
Strict patient confidentiality was maintained throughout 
the data analysis phase. The study was conducted in 
accord with the Declaration of Helsinki.
results
In the period 1995–2017, 1583 patients had a vitamin 
D study performed on 2099 occasions. Of these, 1168 
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patients were treated for opioid dependence and 415 
patients were treated for general medical conditions. It 
is noteworthy that 98% of this study was sampled prior 
to the introduction of universal coverage for hepatitis C 
treatment in Australia in March 2016.
Overall, there were 1061 men and 522 women. Out of 
1168 ODPs, 847 (72.52%) were men and out of 415 GMCs, 
214 (51.57%) were men (Mantel-Haenszel χ2=60.77, 
p<0.0001). In the longitudinal sample including repeat 
tests, 1031/1437 (71.75%) of opioid-dependent samples 
were from men and 350/662 (52.87%) of the general 
medical samples were taken from men (Mantel-Haenszel 
χ2=71.72, p<0.0001).
Patients were considered to be hepatitis C positive 
if either the HCV antibody or their serum PCR study 
was positive for hepatitis C RNA. Among the ODPs, 
301 were hepatitis C antibody seronegative and 867 
were antibody positive. Among the medical controls, 
406 were untested, 1 was seronegative and 8 were 
positive. Hence, 74.23% of the ODPs were hepatitis 
Table 1 Bivariate comparisons—initial cross-sectional data
Valid N Mean (+SEM) Statistics
Control ODP Control ODP t df P value
All patients—initial values
  Age (years) 176 739 41.22 (1.32) 33.92 (0.31) −5.38 194.71 <0.0001
  Haemoglobin (g/dL) 167 731 142.65 (1.00) 147.23 (0.50) 3.98 896.00 0.0001
  Platelets (×109/L) 166 728 267.72 (4.98) 267.81 (2.65) 0.01 892.00 0.9882
  White cell count (×109/L) 167 731 7.95 (0.59) 8.4 (0.09) 0.75 173.80 0.4515
  Neutrophil absolute (×109/L) 167 731 4.91 (0.60) 4.97 (0.08) 0.10 171.52 0.9169
  Lymphocyte absolute (×109/L) 167 731 2.82 (0.60) 2.54 (0.03) −0.47 167.06 0.6401
  Monocytes absolute (×109/L) 167 731 1.18 (0.60) 0.65 (0.01) −0.88 166.07 0.3813
  ESR (mm/hour) 167 720 12.08 (1.20) 10.88 (0.37) −0.95 198.43 0.3408
  High-sensitivity CRP (mg/dL) 166 739 6.21 (1.75) 6.93 (0.50) 0.54 903.00 0.5921
  Total bilirubin (mmol/L) 171 739 10.85 (0.66) 8.1 (0.18) −3.99 196.36 0.0001
  Alkaline phosphatase (IU/L) 171 739 80.87 (3.81) 81.33 (1.05) 0.12 196.52 0.9070
  ALT (IU/L) 171 739 29.24 (1.63) 80.59 (9.11) 5.55 782.28 <0.0001
  AST (IU/L) 171 739 28.26 (1.03) 60.21 (8.40) 3.78 759.46 0.0002
  LDH (IU/L) 171 738 172.84 (2.91) 199.87 (6.00) 2.15 907.00 0.0315
  GGT (IU/L) 171 739 33.27 (2.61) 51.25 (2.32) 5.14 477.24 <0.0001
  Total protein (g/L) 171 739 73.28 (0.39) 75.03 (0.19) 3.96 908.00 0.0001
  Albumin (g/L) 171 739 43.47 (0.40) 42.76 (0.12) −2.20 908.00 0.0278
  Globulin (g/L) 171 739 30.4 (0.49) 32.26 (0.15) 4.75 908.00 <0.0001
  Cholesterol (mmol/L) 171 739 5.64 (0.57) 4.55 (0.04) −1.90 171.53 0.0586
  Triglyceride (mmol/L) 171 739 2.15 (0.61) 1.45 (0.04) −1.15 171.29 0.2500
  LDL (mmol/L) 84 717 14.55 (3.49) 2.38 (0.03) −3.49 83.01 0.0008
  HDL (mmol/L) 84 717 13.25 (3.54) 1.24 (0.02) −3.39 83.00 0.0011
  Vitamin D (nmol/L) 176 739 57.06 (1.81) 70.35 (1.16) 6.19 334.41 <0.0001
Case–control series
Paired t-tests
  Age (years) 331 331 40.08 (0.62) 40.34 (0.64) 5.5716 330.00 <0.0001
  Vitamin D (nmol/L) 331 331 59.73 (1.66) 64.24 (1.52) 2.0044 330.00 0.0458
Non-paired t-tests
  ALT (IU/L) 303 331 32.59 (1.47) 61.74 (7.20) 6.8776 593.15 <0.0001
  AST (IU/L) 303 331 28.41 (0.83) 49.22 (3.17) 8.9718 547.13 <0.0001
  Globulin (g/L) 303 331 30.31 (0.21) 33.18 (0.25) 8.7564 629.68 <0.0001
  High-sensitivity CRP (mg/dL) 272 329 5.26 (0.73) 6.34 (0.76) 2.4738 578.35 0.0137
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; ESR, erythrocyte sedimentation 
rate; GGT, gamma-glutamyl transferase; HDL, high-density lipoprotein; LDH, lactate dehydrogenase; LDL, low-density 
lipoprotein; ODP, opioid-dependent patient.
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C seropositive, compared with only 1.93% (8/415) 
of the GMCs (Mantel-Haenszel extended χ2 test for 
trend=12300.10, p<0.0001).
Table 1 gives the initial bivariate cross-sectional compar-
ative data for selected laboratory parameters. In partic-
ular, one notes a significant difference in chronological 
age between the opioid-dependent and general medical 
groups 33.92±0.31 versus 41.22±1.32 years (mean±SEM, 
t=5.38, sep. var. df=194.71, p<0.0001). Several of the liver 
tests are higher in the opioid-dependent group. Some of 
the lipid parameters are lower likely reflecting a lower 
body weight as has previously been reported in patients 
from this cohort.7 Drug use data in this cohort have been 
previously reported.7 23 44–46
One notes that the vitamin D level is much higher in 
the ODPs 70.35±1.16 vs 57.06±1.81 mmol/L than in the 
GMCs (t=6.19, sep. var. df=334.41, p<0.0001). Low levels 
of vitamin D (<50 nmol/L) were less frequent in the 
ODP group than in the GMC group (27.48% vs 45.3%, 
OR=0.46, 95% CI 0.36 to 0.58, Mantel-Haenszel χ2=44.53, 
df=1, p<0.0001).
Vitamin D levels in the cohort is charted by age in 
figure 1A,B and by time in figure 2 (see the online supple-
mentary figure 1) provides a similar plot to figure 1A but 
is drawn with loess curves which closely approximate 
straight lines, confirming the utility of linear modelling 
in this analysis. The effect of time is shown in the online 
supplementary figure 2, where it is shown that linear 
modelling approximates the effect of passing time less 
well.
ALT is a well-recognised clinical biomarker of metabolic 
ageing.39 47 (Log) vitamin D level was shown to correlate 
with the (log) serum ALT in opioid dependence both in 
the cross-sectional initial group (Spearman R=0.0951, 
t=3.26, df=1166, p=0.0011) and the longitudinal group 
(Spearman R=0.0984, t=3.75, df=1435, p=0.0002). This 
correlation was not significant among GMCs. Another 
biomarker, serum globulin, was not significantly 
correlated with vitamin D in any group.
These figures show a clear age effect. Hence, the very 
different ages in our two major groups may have had an 
effect on the parameter of interest. This age disparity 
was addressed in two ways. First by using a case–control 
comparison group from within the larger group, and 
second by using multiple regression and correcting for 
the effects of chronological age.
Case–control series
In the case–control study, it was possible to pair 331 
GMCs with 331 ODPs by age. The age of the ODPs was 
40.07±0.62 years and that of the GMCs was 40.34±0.64 
years (Student’s paired t-test t=7.13, df=330, p<0.0001). 
The mean difference in ages was 0.26 years. However, the 
ages were not significantly different if a non-paired t-test 
was used (t=0.29, df=660, p=0.76). In 20 of the 331 pairs 
(7.5%) the age difference was >|1|; and in 49/331 pairs 
(14.8%) the age difference was greater than an absolute 
difference of |0.5|. The comparative age distributions are 
shown in superimposed histogram and contour plots (see 
the online supplementary figure 3).
While the two groups had a similar sex ratio, being 
50.76% and 51.36% men, respectively (Mantel-Haenszel 
χ2=0.2, p=0.87) they were not sex-matched at the single 
pair level (Wilcoxson W=53 464, p=0.82).
Selected bivariate parametric comparison from the 
case–control cohort are shown in the lower part of table 1.
The mean vitamin D in these two groups was 
64.24±1.52 and 59.73±1.66, respectively (Student’s paired 
t-test t=5.57, df=330, p<0.0001). These values are charted 
for the initial cross-sectional group in figure 1C.
When the (log) vitamin D status was regressed against 
age in a linear regression model in each case the age: 
addictive status interaction was significant in all patients, 
and in women (top half of table 2). The age: status inter-
action approached significance in men (p=0.066). In a 
linear model quadratic in age, both the addictive status 
and the age squared:status interaction were significant 
(table 2). The model quadratic in age was superior to the 
model linear in age (F=3.422, df=3, p=0.0178).
When the (log) vitamin D level was regressed against 
age and time in a mixed-effects model using restricted 
maximum likelihood modelling techniques, the addictive 
status was significant both in its own right (p=0.0009) and 
in interaction with age (p=0.0180), as show in the top of 
table 3. In a model quadratic in age, the addictive status 
was significant (p=0.0004) and it was also significant in 
interactions with age and time (from p=0.0021). The 
model quadratic in age was superior to the model linear 
in age (log ratio=14.80, df=5, p=0.0112).
Multiple regression in the whole dataset
We then move on to the whole dataset first looking at the 
initial cross-sectional values. In these studies, the (log) 
vitamin D level is regressed against age and addictive 
status. These results are summarised in the lower half of 
table 2 which found significant differences by group and 
by sex.
The effect size between the two groups can be calcu-
lated from this model. When one enters the median age 
(35.83 years) for the cross-sectional dataset in the regres-
sion model, the modelled levels of vitamin D are 62.71 
and 57.81 nmol/L in the ODP and GMC groups, respec-
tively. This represents a 4.90 nmol/L difference or 8.47% 
advancement on the level in the control group.
A model quadratic in age was also calculated for the 
initial cross-sectional data with results shown in the 
lower half of table 2. However, on formal testing, it was 
not superior to the strictly linear model (F=1.7085, df=2, 
p=0.1815).
When all the data (n=2099) are considered in a 
time-dependent mixed-effects model, the results shown 
in the middle portion of table 3 are obtained. In these 
models, the (log) serum vitamin D levels is regressed 
against age, time and drug dependence status with the 
case number as the random effect. A similar model was 
calculated quadratic in age with results shown at the top 
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of table 3. It was found to be superior to the linear model 
(log ratio=8.445, df=3, p=0.0377).
One notes that when sex is included in the model the 
age:time:status interaction is significant. Sex is included 
in one term in the final model. The age:status inter-
action is significant when all patients are considered 
together and in men and women separately. In women, 
this appears as an interaction between time, age and 
Figure 1 Vitamin D and log vitamin D by chronological age, opioid dependency and sex in (A) whole cohort, (B) initial values 
and in (C) case–control study.
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status. These results imply that vitamin D is a biomarker 
of age.
No correlation between vitamin D status and the 
calcium–phosphate solubility product in the whole 
sample was demonstrated (Pearson R=0.019, t=0.86, 
df=2044, p=0.39).
In previous studies, the serum globulins and ALT have 
been the most discriminative clinical pathological vari-
ables and these parameters also show marked age-depen-
dent effects.39 48 49 Therefore, these results were included 
in time-dependent mixed-effects linear regression models 
for all patients and for each sex separately. The outcomes 
of these analyses are shown in the lower part of table 3. In 
each case, the addictive status is significant.
The demonstration that ALT and serum globulins 
are close correlates of the elevated vitamin D in opioid 
dependence raises the question of the possible relation-
ship of liver disease with this observation. Preliminary 
analyses showed that the hepatitis B serostatus was less 
discriminatory than hepatitis C serostatus, so the anal-
ysis in this section focused on hepatitis C. Note that in 
this study, technical factors may blur the definitions of 
the opioid dependence status and hepatitis C serostatus 
as in the present work, as elsewhere,37–39 49–53 the opioid 
dependence status was defined in terms of the hepatitis 
serological results.
The results are as shown in figure 3 where the majority 
of the effect seems to reside with the hepatitis C-positive 
Figure 2 Serum vitamin D status by time in (A) first 3 years and (B) across whole period.
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group. This is formally confirmed by regression analysis 
results shown in the first segment of table 4. However, as 
shown in the lower panels of figure 3, some of the data for 
the hepatitis C serostatus is apparently non-linear. There-
fore, low-order models polynomial in age were compared 
with the linear model. The results of the model quadratic 
in age are shown in the lower section of table 4. Formal 
model comparison using ANOVA testing confirmed that 
the model quadratic in age was superior to the linear 
model (log ratio 19.83 on 5 df, p=0.0013). A similar model 
quadratic in time failed to converge. A model quadratic 
in both age and time also failed to converge.
A complete mixed-effects model of the multiple regres-
sion correlates of serum vitamin D was therefore constructed 
including age, time, ALT, globulins and hepatitis serostatus 
were included in the model and reduced by the classical 
model reduction procedure. Because of the superiority 
of the quadratic model in the more streamlined analysis 
described in the preceding paragraph, this model included 
a term quadratic in age. Sex was not included in the final 
model as it was not significant in the applicable preceding 
model as noted above. The final model derived by this 
procedure is shown in the third section of table 4. In this 
final model, the only parameter which was independently 
correlated with serum vitamin D was the serum ALT level. 
No quadratic term in age was significant in the final model. 
Interestingly, notwithstanding the inclusion of both glob-
ulins and ALT, the hepatitis C serostatus was significantly 
correlative and was included in 8 of the 12 terms in the 
final model. Terms including hepatitis C seropositivity were 
significant from p<0.0001 and terms including hepatitis C 
seronegativity were significant from p=0.0475.
This final model was shown to be superior to the preceding 
quadratic model without biochemical parameters included 
by ANOVA testing (log ratio=19.53 on df=9, p=0.0021).
DIsCussIOn
The main results of this prospective longitudinal study 
were that the serum vitamin D levels in ODPs were 
higher than that in the general medical controls both 
as a mean level overall and in multiple regression 
Table 2 Age-dependent linear regression cross-sectional analyses
Parameter estimates Model
β-Estimate SE t Value P value F Adj. R2 df P value
Case–control series
Linear model
All patients
  Age:status addicted −0.4778 0.1768 −2.702 0.0073 6.83 0.0613 3, 265 0.0002
  Status addicted 24.8561 11.0893 2.241 0.0258
  Quadratic model
   Status addicted 0.2634 0.0609 4.326 0.0000 0.0961 6.7000 5, 263 <0.0001
   (Age)2:status addicted 3.1664 1.0301 3.074 0.0023
   (Age)2 −2.5316 0.8370 −3.025 0.0027
  Men
   Age:status control −0.4232 0.2288 −1.85 0.0668 2.6300 0.02524 2, 124 0.0760
  Women
   Age −0.0145 0.0038 −3.788 0.0002 9.6000 0.0664 2, 139 0.0001
   Age:status addicted 0.0071 0.0021 3.331 0.0011
All patients
Linear model
  Status addicted 0.4547 0.0852 5.337 <0.0001 0.0585 33.75 3, 1579 <0.0001
  Age:status addicted −0.0071 0.0016 −4.505 <0.0001
  Quadratic model
   Status addicted 0.2112 0.0321 6.572 <0.0001 0.0593 20.95 5, 1577 <0.0001
   Age:status addicted −4.1647 1.3631 −3.055 0.00229
  Men
   Status addicted 0.5628 0.1195 4.709 <0.0001 0.0599 23.52 31, 057 <0.0001
   Age:status addicted −0.0083 0.0019 −4.423 <0.0001
  Women
   Status addicted 0.1723 0.0400 4.308 <0.0001 0.03261 18.56 1, 520 <0.0001
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Table 3 Mixed effects final longitudinal models
Variable
Parameter Model
Value SE df t Value p Value AIC BIC logLik
Case–control series
Linear model
  Status addicted 0.3814 0.1121 118 3.4025 0.0009 1046.232 1077.646 −516.1161
  Age:status addicted −0.0062 0.0026 118 −2.3991 0.0180
  Days 0.0001 0.0000 118 2.3023 0.0231
  Age:days 0.0000 0.0000 118 −2.2675 0.0252
Quadratic model
  Status addicted 0.1798 0.0497 113 3.6176 0.0004 1077.582 1131.343 −526.7911
  (Age)2:days:status addicted −0.0017 0.0005 113 −3.1549 0.0021
  Age:days:status addicted 0.0026 0.0009 113 2.8283 0.0055
  Days:status addicted −0.0001 0.0000 113 −2.7344 0.0073
  Age:status addicted −2.3528 0.8716 113 −2.6995 0.0080
  Age:days −0.0009 0.0004 113 −2.5102 0.0135
  Days 0.0000 0.0000 113 2.1706 0.0321
All patients
  Status addicted 0.4253 0.0588 514 7.2353 0.0000 2737.466 2776.991 −1361.733
  Age:status addicted −0.0072 0.0015 514 −4.8060 0.0000
  Days:status addicted −0.0003 0.0001 514 −4.7578 0.0000
  Age:days 0.0000 0.0000 514 3.7269 0.0002
All patients including sex
  Status addicted 0.3496 0.0637 512 5.4913 0.0000 2745.271 2796.080 −1363.636
  Age:status addicted −0.0072 0.0015 512 −4.7819 0.0000
  Age:days:status addicted 0.0000 0.0000 512 −4.4102 0.0000
  Sex man:status addicted 0.1127 0.0289 512 3.9009 0.0001
  Age:days 0.0000 0.0000 512 3.6454 0.0003
Men
  Age:status addicted −0.0084 0.0018 317 −4.6726 0.0000 1809.922 1851.731 −896.9608
  Status addicted 0.4560 0.1124 317 4.0554 0.0001
  Days:status control 0.0002 0.0001 317 2.7606 0.0061
  Days:status addicted −0.0001 0.0001 317 −2.7125 0.0070
Women
  Age:days:status addicted 0.0000 0.0000 193 −3.3598 0.0009 984.101 1011.518 −486.0503
  Status addicted 0.1027 0.0381 193 2.6984 0.0076
  Age:days 0.0000 0.0000 193 2.5055 0.0131
All patients including biochemistry
  ALT:status addicted 0.1022 0.0191 442 5.3506 0.0000 2641.788 2703.304 −1309.894
  Age:ALT:status addicted −0.0018 0.0004 442 −4.4320 0.0000
  Age:days:ALT:globulin:status addicted 0.0000 0.0000 442 −3.3350 0.0009
  Age:days:ALT:globulin:Status control 0.0000 0.0000 442 2.8871 0.0041
  ALT:globulin:status control −0.0107 0.0050 442 −2.1345 0.0334
Males with biochemistry
  ALT:status addicted 0.1022 0.0209 281 4.8779 0.0000 1862.039 1924.291 −919.0196
  Age:ALT:status addicted −0.0020 0.0005 281 −4.3398 0.0000
  Days:ALT:status addicted −0.0001 0.0000 281 −3.9903 0.0001
  Days:ALT 0.0001 0.0000 281 2.8297 0.0050
  Age:days:ALT:globulin 0.0000 0.0000 281 −2.3787 0.0180
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models by dependency status and/or by the age: depen-
dency status interaction in both sexes. The advance in 
the modelled vitamin D level with age was shown to be 
8.47%. The vitamin D level did not change with age in 
the control group, but it did fall significantly with age 
in the opioid-dependent group, making it a negative 
biomarker of ageing in this group. It was also shown to 
be significantly correlated with ALT, a well-recognised 
biomarker of age. Many differences exist between the 
ODPs and GMCs, however the effect appeared to be 
robust to adjustment for many of these features. While 
hepatitis C was an important predictor of the vitamin D 
level, it did not account for the effect of opiate depen-
dency, as it was also observed in the HCV seronegative 
group. On multivariate analysis, vitamin D level was 
found to be significantly associated with interactive 
terms including ALT and measures of immune function 
such as serum globulins. The reasons for the higher 
levels of vitamin D in the opioid-dependent group are 
not clear and the present work is not designed as a 
mechanistic exploration. Unpublished data from this 
cohort show that the socioeconomic profile of the ODP 
and GMC groups is very different, with many more 
tradesmen and welfare-dependents in the ODP group 
which might be expected to have higher and lower 
than normal sun exposure, respectively. The primary 
analyte in this study was 25-hydroxyvitamin D. As the 
25-hydroxylation reaction occurs photolytically in the 
skin, it may be that the higher vitamin D level in the 
ODP in this study reflects increased occupational expo-
sure. It should be noted that the study was conducted 
in Queensland, Australia which has such a high inci-
dence of skin malignancy that it is commonly referred 
to as the ‘melanoma capital of the world’.54 Opioids 
are well known to have various endocrine35 50 53 55–57 
and immune potentiating actions35–38 49 51 58 which have 
been addressed elsewhere and it is possible that indi-
rect effects on vitamin D metabolism may be mediated 
through such pathways. Moreover, the relationship with 
vitamin D status and the square of chronological age was 
fascinating and suggests a positive feed forward process 
as has been found for arterial stiffness in various drug 
dependencies.7 59 60
Although both elevated levels of vitamin D on the 
one hand (present report) and calcium and phosphate 
and their solubility products on the other hand22 have 
been noted in our patients in opioid dependency, as 
no correlation was established between the two sets of 
parameters, it is unlikely based on the present anal-
ysis that a direct relationship exists between them. 
However, as the vitamin D-binding globulin (VDBG) 
has not been measured in the present work, it may be 
that this provides the computational and mechanistic 
‘missing link’ between the two groups of data. More-
over as the vitamin D binding globulin (VDBG, Group 
Specific Component Globulin, gc component, gc glob-
ulin) is generated in the liver61 62 and liver dysfunction 
has been well described both in opioid dependency and 
in HCV infection, this is an important issue for future 
workers in this area. At the time of writing however, 
we are not aware that such assays are available in this 
country. Parallel analyses have found that this situation 
is of particular relevance to the case of the circulating 
levels of sex hormones and their binding globulin in 
men and women in our cohort53 and it may well be the 
case therefore in the case of vitamin D physiology. It 
is important to underscore that the highly significant 
results obtained in the present analysis for the patients 
with hepatitis C seronegative opioid dependency imply 
that hepatic dysfunction alone is not likely to account 
for the observations reported herein. Biomarkers of 
ageing have been reported to be derived from any vari-
able which changes with age.39 Such biomarkers can 
change in either a positive or negative direction with 
age. Both ALT and globulins rise dramatically with 
age and so have been described as positive age-related 
Variable
Parameter Model
Value SE df t Value p Value AIC BIC logLik
  Days:ALT:globulin 0.0003 0.0001 281 2.3190 0.0211
  Age:days:globulin 0.0000 0.0000 281 2.3006 0.0221
  Days:globulin −0.0010 0.0005 281 −2.2099 0.0279
Females with biochemistry
  Globulin:status addicted 0.2158 0.0669 150 3.2246 0.0015 979.508 1037.669 −476.754
  Age:globulin:status addicted −0.0076 0.0024 150 −3.1375 0.0021
  Age:dd:ALT:globulin:status addicted 0.0000 0.0000 150 −2.9772 0.0034
  ALT:globulin −0.0394 0.0139 150 −2.8385 0.0052
  Age:ALT:globulin:status addicted 0.0016 0.0006 150 2.8339 0.0052
  Age:days:ALT 0.0000 0.0000 150 2.5096 0.0132
  Age:days 0.0000 0.0000 150 −2.3426 0.0205
AIC, Akaike Information Criterion; ALT, alanine aminotransferase; BIC, Bayesian Information Crieterion; DD, days; logLik, Log Likelihood ratio.
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biomarkers.37 38 49 51 63 In the ODPs described in the 
present study, vitamin D levels fell with age which would 
make vitamin D a negative biomarker of age in the 
drug-dependent cohort (tables 2–4, figures 1 and 3A,B 
and see the online supplementary figure 1). Moreover, 
vitamin D status was also shown to correlate with ALT in 
drug dependence which is a well-established biomarker 
of ageing.
Interestingly very high levels of osteoporosis/oste-
opaenia have been noted in ODP groups by several 
Figure 3 Logarithm vitamin D by hepatitis C serostatus by: (A) age and sex using linear lines of best fit; (B) age and sex using 
loess (localised polynomial) curves of best fit and (C) over the first 3 years by sex.
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Table 4 Mixed effects final longitudinal models by hepatitis C serostatus
Variable
Parameter Model
Value SE df t Value P value AIC BIC logLik
Case-control series
Linear model
  Status addicted 0.3814 0.1121 118 3.4025 0.0009 1046.232 1077.646 −516.1161
  Age: status addicted −0.0062 0.0026 118 −2.3991 0.0180
  Days 0.0001 0.0000 118 2.3023 0.0231
  Age: days 0.0000 0.0000 118 −2.2675 0.0252
Quadratic model
  Status addicted 0.1798 0.0497 113 3.6176 0.0004 1077.582 1131.343 −526.7911
  (Age)2: days: status addicted −0.0017 0.0005 113 −3.1549 0.0021
  Age: days: status addicted 0.0026 0.0009 113 2.8283 0.0055
  Days: status addicted −0.0001 0.0000 113 −2.7344 0.0073
  Age: status addicted −2.3528 0.8716 113 −2.6995 0.0080
  Age: days −0.0009 0.0004 113 −2.5102 0.0135
  Days 0.0000 0.0000 113 2.1706 0.0321
All patients
  Status addicted 0.4253 0.0588 514 7.2353 0.0000 2737.466 2776.991 −1361.733
  Age: status addicted −0.0072 0.0015 514 −4.8060 0.0000
  Days: status addicted −0.0003 0.0001 514 −4.7578 0.0000
  Age: days 0.0000 0.0000 514 3.7269 0.0002
All patients including sex
  Status addicted 0.3496 0.0637 512 5.4913 0.0000 2745.271 2796.080 −1363.636
  Age: status addicted −0.0072 0.0015 512 −4.7819 0.0000
  Age: days: status addicted 0.0000 0.0000 512 −4.4102 0.0000
  Sex male: status addicted 0.1127 0.0289 512 3.9009 0.0001
  Age: days 0.0000 0.0000 512 3.6454 0.0003
Men
  Age: status addicted −0.0084 0.0018 317 −4.6726 0.0000 1809.922 1851.731 −896.9608
  Status addicted 0.4560 0.1124 317 4.0554 0.0001
  Days: status control 0.0002 0.0001 317 2.7606 0.0061
  Days: status addicted −0.0001 0.0001 317 −2.7125 0.0070
Women
  Age: days: status addicted 0.0000 0.0000 193 −3.3598 0.0009 984.101 1011.518 −486.0503
  Status addicted 0.1027 0.0381 193 2.6984 0.0076
  Age: days 0.0000 0.0000 193 2.5055 0.0131
All patients including biochemistry
  ALT: status addicted 0.1022 0.0191 442 5.3506 0.0000 2641.788 2703.304 −1309.894
  Age: ALT: status addicted −0.0018 0.0004 442 −4.4320 0.0000
  Age: days: ALT: globulin: status 
addicted
0.0000 0.0000 442 −3.3350 0.0009
  Age: days: ALT: globulin: status control 0.0000 0.0000 442 2.8871 0.0041
  ALT: globulin: status control −0.0107 0.0050 442 −2.1345 0.0334
Males with biochemistry
  ALT: status addicted 0.1022 0.0209 281 4.8779 0.0000 1862.039 1924.291 −919.0196
  Age: ALT: status addicted −0.0020 0.0005 281 −4.3398 0.0000
  Days: ALT: status addicted −0.0001 0.0000 281 −3.9903 0.0001
  Days: ALT 0.0001 0.0000 281 2.8297 0.0050
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authors.5 64–66 Clearly the higher levels of vitamin D seen 
in this study are not in accordance with such a finding. 
However, an inverse effect may be mediated by either a 
higher level of VDBG or a block to the metabolism of 
vitamin D to the active form 1,25-dihydroxycholecalcif-
erol. Such a finding must await further studies. More-
over, the generally immunologically activated milieu of 
opiate dependence is now increasingly well character-
ised.35 37 39 49 63 It may be that the immune active environ-
ment, with higher levels of interleukin-1, interleukin-6, 
tumor necrosis factor-alpha and Monocyte Chemotactic 
Protein 1/Chemokine (C-C motif) Ligand 2 (MCP-1/
CCL2) among other key cytokines,67 is the dominant 
force acting on bone mineralisation and overwhelms 
any relatively minor effect related to vitamin D metab-
olism. Interestingly melanocortin receptor-1 has been 
identified in the skin.68 P53-induced photoactivation of 
pro-opiomelanocortin synthesis has been shown to be 
linked with cutaneous β-endorphin release, elevated pain 
thresholds and naloxone-inducible withdrawal after sun 
exposure. It is therefore potentially possible that ODPs 
may be self-medicating the possibility of withdrawal by 
elevating their rate of sun exposure.69 Further intriguing 
conceptual possibilities emerge. Opioid dependence is 
characterised by a subtle disruption of normal metabo-
lism39 70 to the extent where patients have been compared 
with prediabetics.50 56 71 72 Moreover, and in common with 
many addictions, opioid dependence is characterised by 
a marked immune stimulation36 37 39 58 73 and simulation 
or at least phenocopying of the ageing process.6 7 9 39 45 74 
It turns out that nuclear hormone receptors (NHRs) of 
various classes facilely integrate such immunometabolic 
signalling.75–80 NHRs of the oestrogen, androgen, preg-
nane, peroxisome proliferator activator receptor, liver 
X receptor and rexinoids are involved along with the 
vitamin D receptor.75 78 79 Importantly, there is signif-
icant heterodimerisation and apparent promiscuity 
with many of these receptors81–83 including the vitamin 
D receptor84–90 and involvement of these pathways in 
diverse cell processes including stem cell regenera-
tion,91–96 atherogenesis78 97–101 and cancer.83 102–106 As 
altered metabolism, immunosenescence, cancerogenesis 
and stem cell failure are all well described in the ageing 
literature,28 29 107–109 it would appear that pathophysiolog-
ically, phenotypically and clinically important processes 
may be impacted by the changes reported in the present 
paper.
This study had various strengths and limitations. 
The large sample size, prospective design, longitudinal 
nature and real-world sampling for the groups were 
major strengths. As the study was taken from ‘real-world 
participants’ and as the opioid use has previously been 
shown to be typical of that reported in many other clin-
ical series, we feel that these results may be generalis-
able to opioid-dependent populations elsewhere. As 
the drug use data were not available in these patients, 
it was not possible to compare drug use levels with 
vitamin D status or calculate dose–response relation-
ships. Similarly, anthropometric including body mass 
index data and sun exposure information is not avail-
able. The extent of vitamin D supplementation used 
by patients is also unknown, but it is believed that its 
use would be more widespread among controls than in 
ODP, thereby acting in the reverse direction. Socioeco-
nomic and occupational data were also not available to 
the present study. While every attempt has been made 
to adjust the findings for measured confounding vari-
ables, the involvement of unmeasured confounding 
in the present results is not known. Nevertheless, the 
robustness of the present findings to various data 
manipulations including longitudinal and multivariate 
adjustment suggests that the finding is genuine. These 
findings could be supported by future mechanistic and 
interventional studies. The unavailability of VDBG assay 
Variable
Parameter Model
Value SE df t Value P value AIC BIC logLik
  Age: days: ALT: globulin 0.0000 0.0000 281 −2.3787 0.0180
  Days: ALT: globulin 0.0003 0.0001 281 2.3190 0.0211
  Age: days: globulin 0.0000 0.0000 281 2.3006 0.0221
  Days: globulin −0.0010 0.0005 281 −2.2099 0.0279
Females with biochemistry
  Globulin: status addicted 0.2158 0.0669 150 3.2246 0.0015 979.508 1037.669 −476.754
  Age: globulin: status addicted −0.0076 0.0024 150 −3.1375 0.0021
  Age: dd: ALT: globulin: status addicted 0.0000 0.0000 150 −2.9772 0.0034
  ALT: globulin −0.0394 0.0139 150 −2.8385 0.0052
  Age: ALT: globulin: status addicted 0.0016 0.0006 150 2.8339 0.0052
  Age: days: ALT 0.0000 0.0000 150 2.5096 0.0132
  Age: days 0.0000 0.0000 150 −2.3426 0.0205
AIC, Akaike Information Criterion; ALT, alanine aminotransferase; BIC, Bayesian Information Crieterion; log Lik, Log Likelihood ratio. 
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or studies of vitamin D nuclear receptor to the present 
work were limitations.
In summary, the present work quantitated vitamin D 
status for the first time in a patient cohort dependent on 
illicit opioids and demonstrated higher vitamin D levels 
in the opioid-dependent group both as a group mean, 
in case–control and after adjustment for age, sex and 
selected laboratory markers in various linear regression 
models. The modelled level was 8.47% higher in the 
OPD than in controls. The effect was not simply attribut-
able to hepatitis C infection. The cause of this elevation 
was not clear from the present report. Vitamin D levels 
fell with age in ODPs, making it a negative biomarker of 
ageing in this cohort. This finding is of interest due to 
the described involvement of NHRs (including vitamin 
D receptor) with inflammatory and metabolic pathways 
which may be of clinical significance and may relate 
to the well-described ageing phenotype observed in 
opioid-dependent populations. Future studies should 
consider including detailed parametric drug use histo-
ries, occupational exposure to sunlight and measure-
ment of VDBG or vitamin D receptor activity and active 
vitamin D metabolites in further exploring this issue.
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